CLAIM LISTING

1-28. Canceled.

29. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the method does not include treatment with a radiolabeled antibody.

30. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg.

31. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg.

32. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg.

33. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m^2.

34. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m^2.

35. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m^2.

36. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 650 mg/m^2.

37. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 825 mg/m^2.

38. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 1500 mg/m^2.

39. (Previously presented) A method according to claim 29 or 34, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia.

40. (Previously presented) A method according to claim 29 or 34, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia.

41. (Currently amended) A method according to claim 40, wherein the patient is refractory to ~~fludaribine~~ fludarabine.

42. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a chimeric antibody.

43. (Previously presented) A method according to claim 42, wherein the anti-CD20 antibody is rituximab.

44. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a humanized antibody.

45. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a human antibody.

46. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody.

47. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is administered to the patient repeatedly.

48. (Previously presented) A method according to claim 47, wherein the repeated administration comprises a stepped-up dosing schedule.

49. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient weekly.

50. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks.

51. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient biweekly.

52. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient monthly.

53. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is administered to the patient parenterally.

54. (Previously presented) A method according to claim 53, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion.

55. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody therapy is combined with chemotherapy, wherein the method does not include treatment with a radiolabeled antibody.

56. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg.

57. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg.

58. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg.

59. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m^2.

60. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m^2, and wherein the anti-CD20 antibody therapy is combined with chemotherapy.

61. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m^2.

62. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 650 mg/m^2.

63. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 825 mg/m^2.

64. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 1500 mg/m^2.

65. (Previously presented) A method according to claim 55 or 60, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia.

66. (Previously presented) A method according to claim 55 or 60, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia.

67. (Currently amended) A method according to claim 66, wherein the patient is refractory to ~~fludaribine~~ fludarabine.

68. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a chimeric antibody.

69. (Previously presented) A method according to claim 68, wherein the anti-CD20 antibody is rituximab.

70. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a humanized antibody.

71. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a human antibody.

72. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody.

73. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is administered to the patient repeatedly.

74. (Previously presented) A method according to claim 73, wherein the repeated administration comprises a stepped-up dosing schedule.

75. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient weekly.

76. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks.

77. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient biweekly.

78. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient monthly.

79. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is administered to the patient parenterally.

80. (Previously presented) A method according to claim 79, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion.

81. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody therapy and the chemotherapy are administered to the patient concurrently.

82. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises chlorambucil.

83. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises cyclophosphamide.

84. (Currently amended) A method according to claim 83, wherein the chemotherapy comprises cyclophosphamide, ~~Oncovin~~ vincristine, and prednisone (COP).

85. (Currently amended) A method according to claim 83, wherein the chemotherapy comprises cyclophosphamide, ~~Oncovin~~ vincristine, prednisone, and doxorubicin (CHOP).

86. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises vincristine.

87. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises prednisone.

88. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises doxorubicin.

89. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises fludarabine.

90. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises methotrexate.

91. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises cisplatin.

92. (Currently amended) A method according to claim 55 or 60, wherein the chemotherapy comprises ~~toremifine~~ toremifene.

93. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises tamoxifen.

94. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an ~~unlabeled~~ anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the patient is refractory to ~~fludaribine~~ fludarabine previously administered for the chronic lymphocytic leukemia.

95. (New) A method according to claim 34, 60, or 94, wherein the method does not include treatment with a radiolabeled antibody.

96. (New) A method according to claim 34, 60, or 94, wherein radiation is not used in conjunction with the anti-CD20 antibody.

97. (New) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering a therapeutic anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein radiation is not used in conjunction with the therapeutic anti-CD20 antibody.

98. (New) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering a therapeutic anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody therapy is combined with chemotherapy, and wherein radiation is not used in conjunction with the therapeutic anti-CD20 antibody.